This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (35)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Malcolm S. Artenstein, MD

JAMA. 1975;231(10):1035-1037.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE PAST decade has been a tumultuous one for meningococcologists. The emergence and spread of sulfadiazine-resistant strains, which were first reported in 1963, ended a 20-year period in which control of the dreaded disease was possible with a brief, inexpensive chemoprophylactic regimen (sulfadiazine, 2 gm a day for two days). Intensive research over the next six years led to the development of purified capsular polysaccharide vaccines.¹ These were subsequently proved to be effective in preventing disease caused by serogroup C and serogroup A organisms. Meningococcal disease in the United States has been at a low ebb in recent years even though vaccines have not been available for general use.

Other countries have not been so fortunate. Epidemic meningitis in Brazil has been commanding considerable newspaper coverage recently. Since 1971, Sao Paulo has experienced an epidemic of sulfadiazine-resistant serogroup C disease, with an overall rate of 11.3/100,000 total population per . . . [Full Text PDF of this Article]

Author Affiliations
Washington, DC

From the Department of Bacterial Diseases, Division of Communicable Diseases and Immunology, Walter Reed Army Institute of Research, Washington, DC.

Footnotes
Reprint requests to Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, DC 20012 (Dr. Artenstein).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?